In this edition, AYA cancer survivors are at higher risk for death due to second primary cancers; a radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer; a phase 3 trial of tiragolumab plus atezolizumab misses its co-primary endpoint; and more.
Read the full coverage here:
AYA cancer survivors at higher risk for death due to second primary cancers
Radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer
Phase 3 trial of combination for advanced lung cancer misses co-primary endpoint
As proton beam therapy use for cancer increased, ‘so did the racial disparity in receipt’
Entrectinib induces durable, intracranial responses in NTRK fusion-positive solid tumors
References:
Sung H, et al. J Natl Cancer Inst. 2022;doi:10,1093/jnci/djac091.
Louie AV, et al. JAMA Oncol. 2022:doi:10.1001/jamaoncol.2021.7664.
Nogueira LM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8970.
Demetri GD, et al. Clin Cancer Res. 2022;doi:10.1158/1078-0432.CCR-21-3597.
